Hospital
Ascension Wisconsin Emerus Menomonee Falls, LLC
Ascension Wisconsin Emerus Menomonee Falls, LLC was paid $1.83M by Medicaid between Dec 2021 and Dec 2024, across 70 billing codes. Its largest line is 99283, emergency room visit (moderate) — 29% of everything it billed.
33Billing provider infoASCENSION WISCONSIN EMERUS MENOMONEE FALLS, LLC
MENOMONEE FALLS, WI 53501
MENOMONEE FALLS, WI 53501
33aNPI1063018927assigned 12/07/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.83M
24GClaims72,780
24DCodes billed70
24AFirst – last monthDec 2021 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#37 of 60
Median peer was paid$2.90M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 620 | $16K | |
| 2022 | 18,173 | $416K | |
| 2023 | 28,057 | $689K | |
| 2024incomplete | 25,930 | $711K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 8,443 | 7,654 | $534K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 4,452 | 3,954 | $279K |
| 96361 | Intravenous infusion, hydration; each additional hour | 11% | 1,472 | 1,227 | $206K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 2,772 | 2,533 | $190K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.2% | 1,961 | 1,822 | $131K |
| 87428 | 4.5% | 2,496 | 2,305 | $83K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 566 | 528 | $43K |
| 80053 | Comprehensive metabolic panel | 1.7% | 2,118 | 1,865 | $31K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.6% | 448 | 413 | $30K |
| 80051 | 1.5% | 2,374 | 2,076 | $28K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 4,380 | 3,749 | $26K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 281 | 248 | $23K |
58 more codes
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.2% | 1,219 | $22K |
| 81003 | 1.1% | 3,457 | $20K | |
| 81025 | 1.0% | 2,437 | $18K | |
| 84484 | <1% | 1,366 | $14K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 679 | $12K |
| 82550 | <1% | 2,405 | $12K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 672 | $11K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 282 | $10K |
| 82947 | <1% | 2,797 | $10K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 136 | $9K |
| 82565 | <1% | 2,376 | $9K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 498 | $8K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 153 | $7K |
| 84520 | <1% | 2,374 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 59 | $6K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 82 | $5K |
| 87634 | <1% | 137 | $5K | |
| 82977 | <1% | 720 | $4K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 71 | $4K |
| 82150 | <1% | 730 | $4K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 135 | $4K |
| 84460 | <1% | 719 | $3K | |
| 83605 | <1% | 314 | $3K | |
| 84075 | <1% | 718 | $3K | |
| 84450 | <1% | 719 | $3K | |
| 82040 | <1% | 719 | $3K | |
| 87420 | <1% | 123 | $3K | |
| 85379 | <1% | 299 | $2K | |
| 82247 | <1% | 718 | $2K | |
| 84702 | <1% | 148 | $2K | |
| 84155 | <1% | 718 | $2K | |
| 87400 | <1% | 62 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,807 | $840.15 |
| 80305 | <1% | 36 | $592.04 | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,720 | $389.58 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 15 | $362.01 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 90 | $346.99 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 15 | $327.02 |
| 87210 | <1% | 271 | $274.21 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,801 | $172.78 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 26 | $146.96 |
| 87807 | <1% | 13 | $138.92 | |
| 87808 | <1% | 12 | $129.40 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 381 | $95.14 |
| 87905 | <1% | 12 | $90.69 | |
| 85027 | <1% | 14 | $81.29 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,191 | $42.77 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 699 | $41.33 |
| 73130 | <1% | 13 | $24.03 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,275 | $18.98 |
| 96376 | <1% | 238 | $13.44 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 303 | $3.58 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 788 | $1.04 |
| 73562 | 0% | 57 | $0.00 | |
| 73610 | 0% | 54 | $0.00 | |
| 73630 | 0% | 30 | $0.00 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 28 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 86 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSCHMERBECK, VICTOR (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| HCN Ep Horizon City, LLC | El Paso, TX | $1.18M |
| Ascension Wisconsin Emerus Menomonee Falls, LLC | Milwaukee, WI | $1.11M |
| Ascension Wisconsin Emerus Menomonee Falls, LLC | Waukesha, WI | $308K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.